Abingworth related stories
All articles and analysis
Side Letter: Ares' APAC acquisition; PE's LP-led lurch; Hawaii's hungry for PEAres Management's second acquisition in under three years makes sense for both parties. Plus: LPs seeking liquidity are keeping the secondaries market ticking over; and Hawaii is hungry for (a little) more private equity. Here's today's brief, for our valued subscribers only.
GP consolidation to deepen in difficult fundraising environment – IPEM panelThe high cost of operations, capital constraints and an attraction to specialists are all factors driving M&A activity among PE firms.
CHART: The biggest dedicated life sciences capital raisersDedicated life sciences firms with strong AUM growth have been prime targets for larger GPs recently – here's a list of firms ranked by capital raised.
Side Letter: Horizon's Ukraine learnings; Apollo's €1bn life sciences buy; Onex fundraising warningHorizon Capital's Lenna Koszarny discusses the Ukrainian firm's efforts to safeguard staff and portco employees in the wake of Russia's invasion. Plus: Apollo has become the latest firm to snap up a life sciences unit and Onex warns fundraising could take longer than usual. Here's today's brief, for our valued subscribers only.
Side Letter: Apollo's BlackRock hires; Carlyle's healthcare booster; Norinchukin’s impactApollo Global Management's appointment of three ex-BlackRock executives highlights the rising demand for secondaries talent in today's private equity market. Plus: Carlyle is the latest PE giant to complete a life sciences acquisition and another Japanese LP wants to make a big impact. Here's today's brief, for our valued subscribers only.
Abingworth raises $582mAbingworth Clinical Co-Development Fund 2 holds a final close.
Abingworth raises $315mThe London-based investment firm closes latest fund above target.
Abingworth raises $115.3mView the latest capital raises
- Private equity heavyweights weigh in on Brexit
Data from the Electoral Commission shows industry names, including KKR’s Johannes Huth and Warburg Pincus’ Joseph Schull, are not leaving the outcome of the upcoming referendum to chance.
- Abingworth closes 11th life sciences fund on $105m
Many investors in the Abingworth Clinical Co-Development Fund were family offices and funds of funds.